Frequency of liver test increases on abiraterone acetate in men with castrate-resistant prostate cancer (CRPC): Natural history, management, and outcome.

被引：0
|
作者：
Colomba, Emeline
Marret, Gregoire
Baciarello, Giulia
Massard, Christophe
Loriot, Yohann
Albiges, Laurence
Carton, Edith
Alexandre, Jerome
Huillard, Olivier
Culine, Stephane
Fizazi, Karim
机构：
[1] Univ Paris Sud, Gustave Roussy Inst Oncol, Villejuif, France
[2] St Louis Hosp, Paris, France
[3] Gustave Roussy Canc Campus, Villejuif, France
[4] Inst Gustave Roussy, Villejuif, France
[5] Univ Paris 05, Hop Cochin, CARPEM, AP HP, Paris, France
[6] Paris Descartes Univ, Cochin Hosp, Immunomodulatory Therapies Multidisciplinary Stud, AP HP,CARPEM, Paris, France
[7] Hosp St Louis, Paris, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 06期
关键词：
D O I：
10.1200/JCO.2018.36.6_suppl.332
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
332
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A pilot study of supraphysiologic testosterone (T) and oral etoposide (E) in men with castrate-resistant prostate cancer (CRPC)
    Schweizer, Michael Thomas
    Antonarakis, Emmanuel S.
    Wang, Hao
    Spitz, Avery N.
    Cao, Haiyi
    Pacheco, Alberto
    Eisenberger, Mario A.
    Carducci, Michael Anthony
    Denmeade, Samuel R.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [22] Validation of a prognostic model for metastatic castrate-resistant prostate cancer (mCRPC) patients receiving abiraterone acetate (AA).
    Ravi, Praful Kumar
    Mateo, Joaquin
    Zafeiriou, Zafeiris
    Altavilla, Amelia
    Ferraldeschi, Roberta
    Sideris, Spyridon
    Grist, Emily
    Smith, Alan D.
    Wong, Sophia
    Lorente, David Look
    Bianchini, Diletta
    Attard, Gerhardt
    De Bono, Johann Sebastian
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [23] A Phase Ib study of BKM120 combined with abiraterone acetate for castrate-resistant, metastatic prostate cancer
    Patnaik, A.
    Kung, J.
    Wu, J.
    Loda, M.
    Kantoff, P.
    Cantley, L. C.
    Balk, S.
    Bubley, G.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S171 - S171
  • [24] A Phase Ib study of BKM120 combined with abiraterone acetate for castrate-resistant, metastatic prostate cancer
    Patnaik, Akash
    Loda, Massimo
    Kung, Justin
    Wu, Jim
    Taplin, MaryEllen
    Kantoff, Philip
    Cantley, Lewis
    Balk, Steven
    Bubley, Glenn
    CANCER RESEARCH, 2014, 74 (19)
  • [25] Prognostic factors for patients with metastatic castrate-resistant prostate cancer (mCRPC) receiving abiraterone acetate prechemotherapy.
    Charnley, Natalie
    Birtle, Alison J.
    Swindell, Ric
    Parikh, Omi
    Wise, Marcus
    Kumar, Varadarajan
    Danwata, Falalu Dahiru
    Thompson, Catherine
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [26] A pilot study of supraphysiologic testosterone (T) and oral etoposide (E) in men with castrate-resistant prostate cancer (CRPC).
    Schweizer, Michael Thomas
    Antonarakis, Emmanuel S.
    Wang, Hao
    Spitz, Avery N.
    Cao, Haiyi
    Pacheco, Alberto
    Eisenberger, Mario A.
    Carducci, Michael Anthony
    Denmeade, Samuel R.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [27] C11-acetate PET for docetaxel prednisone (DP) response assessment in castrate-resistant prostate cancer (CRPC)
    Sharma, Nancy
    Menda, Yusuf
    Boles-Ponto, Laura
    Vaena, Daniel A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [28] C11-acetate PET for docetaxel prednisone (DP) response assessment in castrate-resistant prostate cancer (CRPC).
    Sharma, Nancy
    Menda, Yusuf
    Boles-Ponto, Laura
    Vaena, Daniel A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [29] Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancer
    Ramalingam, Sundhar
    Humeniuk, Michael S.
    Hu, Rachel
    Rasmussen, Julia
    Healy, Patrick
    Wu, Yuan
    Harrison, Michael R.
    Armstrong, Andrew J.
    George, Daniel J.
    Zhang, Tian
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2017, 35 (06) : 418 - 424
  • [30] Evaluating the hypothalamic-pituitary-adrenal axis (HPAA) in men receiving ketoconazole for castrate-resistant prostate cancer (CRPC)
    Aggarwal, Rahul Raj
    Weinberg, Vivian K.
    Sosa, Eduardo V.
    Lin, Amy M.
    Harzstark, Andrea Lynne
    Small, Eric Jay
    Fong, Lawrence
    Hsieh, Andrew Caleb
    Formaker, Carl
    Koepfgen, Kathryn M.
    Friedlander, Terence W.
    Ryan, Charles J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
12345